Vectorpharma International S.p.a.

Eurand International S.p.a.

Azad Pharma Ag

Chiesi Farmaceutici S.p.a.

Instituto Biochimico Italiano Giovanni Lorenzini S.p.a.

Actimex S.r.l.

Fabio Carli

Tiziana Canal

Mara L Lovrecich

Luca Dobetti

Pierandrea Esposito

Mihran Baronian

Elisabetta Chiellini

Paolo Chiesi

Maria Dorly Del Curto

Alberto Brandt

Paolo Corvi Mora

Massimo Bresciani

Italo Colombo

Fabio Borella

Leonardo Rabaglia

Rene Schmid

Van Van Khov-Tran

Nicoletta Coceani

Paolo Gambini

Daniela Lombardi

Luigi Boltri

Ernest Baehler

René Schmid

The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.

Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules

The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature.

Ophthalmic oil-in-water emulsions containing prostaglandins

The present invention describes a quaternary composition consisting of propolis delivered in a hydrophilic carrier (cyclodextrin and cyclodextrin derivatives) and co ground with the aid of two compounds for the preparation thereof in the form of a finely divided powder. The composition exhibits advantageous dissolution characteristics in aqueous environments compared to native propolis, hence resulting in greater bioavailability of the active ingredients contained therein.

Quaternary compounds comprising propolis as the active substance

The invention provides a biphasic multicomponent pharmaceutical composition consisting of an oil phase and a water phase, comprising one or more lipophilic or oil carrier, one or more hydrophilic or aqueous carrier, one or more ionic or nonionic type surfactant, one or more cosurfactant, one or more active principle for pharmaceutical use, and a compound able to modify the partition of the active principle between said phases selected from the group consisting of N- methyl pyrrolidone (NMP), isopropyl alcohol, propylene glycol, ethoxy-di-glycol, &bgr;-cyclodextrin, hydroxypropyl &bgr;-cyclodextrin and dimethyl &bgr;-cyclodextrin. The invention also provides a method for making the composition.

Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs

Process for the preparation of pharmaceutical compositions comprising one or more polymers and one or more drugs by the extrusion and spheronization technique, wherein polymers belong to the group of the cross-linked amphiphilic polymers.

Pharmaceutical compositions in form of polymeric microparticles obtained by extrusion and spheronization

The pharmaceutical compositions including a slightly soluble drug incorporated in a water-swellable, but water-insoluble cross-linked polymer, a surface active agent, and an oil show much improved dissolution and, consequently, bioavailability in respect of the drug as is or used with a polymeric carrier of said type.

Pharmaceutical compositions including a drug, a cross-linked polymeric

Pharmaceutical compositions in the form of particles comprising a biodegradable polymer and/or a polysaccharide jellifying and/or bioadhesive polymer, an amphiphilic polymer, an agent modifying the interface properties of the particles and a pharmacologically active substance. Said compositions exhibit improved biocompatibility features and allow a controlled release of the active substance.

Pharmaceutical compositions in the form of particles suitable for the

There are described transdermal therapeutic compositions showing an improved shelf stability of the chemical-physical structure of the medicament and particularly useful for its cutaneous administration, said compositions consisting of a supporting rigid sheet, a polymetic matrix and a protective removable sheet, wherein said polymeric matrix consists of a polymeric film in which there are distributed particles loaded with medicaments and agents promoting the cutaneous absorption.

Transdermal therapeutic compositions

A slow-release pharmaceutical composition containing a bile acid as active ingredient and comprising at least one bioadhesive substance and at least one high specific gravity substance, an aliquot thereof being enteric coated and the remainder being non-enteric coated.

Slow release pharmaceutical composition containing a bile acid as an

The described therapeutic compositions with controlled release of medicaments comprise a medicament loaded onto particles of a crosslinked non-ionic polymer insoluble but swellable in water, using either swelling with solutions of the medicament or high-energy co-grinding methods. The medicament-loaded particles are coated with a polymers film able to control medicament release, to obtain a prolonged release of the medicament (even exceeding 24 hours) while maintaining high bioavailability.

Therapeutic compositions with controlled release of medicaments

A process for preparing complexes of piroxicam with cyclodextrins in which the two components in the powder state are premixed and then co-ground in a high energy mill in the presence of steam. The products obtained have technological, physical and biopharmacological characteristics which are advantageous compared with those of liquid-state complexes obtained by traditional methods, and are suitable for preparing pharmaceutical compositions for oral, rectal and topical use.

Growing community of inventors

Trieste, Italy

Fabio Carli